Pfizer (NYSE:PFE) has decided not to further develop sisunatovir, an antiviral targeted at respiratory syncytial virus (RSV), which was part of the company's $525M acquisition of privately held ReViral in 2022, Endpoints News reported Tuesday.
https://seekingalpha.com/news/4157094-pfizer-is-said-to-have-dropped-rsv-candidate-from-pipeline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.